Andres Coca Pelaz

Dr. Andres Coca Pelaz

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
APAndres Coca Pelaz
Andres Coca Pelaz
JSJatin P. Shah
Jatin P. Shah
JHJuan C. Hernandez-Prera
Juan C. Hernandez-Prera
RGRonald A. Ghossein
Ronald A. Ghossein
JRJuan P. Rodrigo
Juan P. Rodrigo
AFAlfio Ferlito
Alfio Ferlito
Introduction Aggressive variants of papillary thyroid cancer (PTC) have been described with increasing frequency. These variants include diffuse sclerosing variant, tall cell variant, columnar cell variant, solid variant, and hobnail variant. Methods We have performed a review of the more aggressive variants of PTC with respect to main characteristics, histological and molecular features, and the consequences that the knowledge of these variants should have in the treatment of the patients. Results At the present time, we do not know the prognostic value of these aggressive PTC variants. The extent of the surgical treatment and adjuvant therapy necessary should be decided on the basis of the extent of the tumor at presentation and the opinion of experienced clinicians. Conclusion These aggressive variants should be known by clinicians, to avoid underdiagnosis, and treated according to the latest recommendations in the literature.

21 November 2019 in Head & Neck
Verified
Journal Article
Closed access
PDF file
APAndres Coca Pelaz
Andres Coca Pelaz
Juan Pablo Rodrigo TapiaJuan Pablo Rodrigo Tapia
Juan Pablo Rodrigo Tapia
CSCarlos Suárez
Carlos Suárez
INIain Nixon
Iain Nixon
AMAntti Mäkitie
Antti Mäkitie
AFAlfio Ferlito
Alfio Ferlito

2 February 2018 in Advances in Therapy
Verified
Journal Article
Closed access
PDF file
APAndres Coca Pelaz
Andres Coca Pelaz
RTRobert P. Takes
Robert P. Takes
KHKate Hutcheson
Kate Hutcheson
NSNabil F. Saba
Nabil F. Saba
MHMissak Haigentz
Missak Haigentz
AFAlfio Ferlito
Alfio Ferlito

24 April 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Alvaro SanabriaAlvaro Sanabria
Alvaro Sanabria
JSJatin P. Shah
Jatin P. Shah
JMJesus E. Medina
Jesus E. Medina
KOKerry D. Olsen
Kerry D. Olsen
KRKevin Robbins
Kevin Robbins
Alfio FerlitoAlfio Ferlito
Alfio Ferlito
Background: Larynx cancer is a common site for tumors of the upper aerodigestive tract. In cases with a clinically negative neck, the indications for an elective neck treatment are still debated. The objective is to define the prevalence of occult metastasis based on the subsite of the primary tumor, T classification and neck node levels involved. Methods: All studies included provided the rate of occult metastases in cN0 larynx squamous cell carcinoma patients. The main outcome was the incidence of occult metastasis. The pooled incidence was calculated with random effects analysis. Results: 36 studies with 3803 patients fulfilled the criteria. The incidence of lymph node metastases for supraglottic and glottic tumors was 19.9% (95% CI 16.4–23.4) and 8.0% (95% CI 2.7–13.3), respectively. The incidence of occult metastasis for level I, level IV and level V was 2.4% (95% CI 0–6.1%), 2.0% (95% CI 0.9–3.1) and 0.4% (95% CI 0–1.0%), respectively. For all tumors, the incidence for sublevel IIB was 0.5% (95% CI 0–1.3). Conclusions: The incidence of occult lymph node metastasis is higher in supraglottic and T3–4 tumors. Level I and V and sublevel IIB should not be routinely included in the elective neck treatment of cN0 laryngeal cancer and, in addition, level IV should not be routinely included in cases of supraglottic tumors.

28 April 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
Juan Pablo Rodrigo TapiaJuan Pablo Rodrigo Tapia
Juan Pablo Rodrigo Tapia
MSMario Sanchez-Canteli
Mario Sanchez-Canteli
Fernando LõpezFernando Lõpez
Fernando Lõpez
GWGregory Wolf
Gregory Wolf
JHJuan C. Hernández-Prera
Juan C. Hernández-Prera
Alfio FerlitoAlfio Ferlito
Alfio Ferlito
The presence of tumor-infiltrating lymphocytes (TIL) in the tumor microenvironment has been demonstrated to be of prognostic value in various cancers. In this systematic review and meta-analysis, we investigated the prognostic value of TIL in laryngeal squamous cell carcinoma (LSCC). We performed a systematic search in PubMed for publications that investigated the prognostic value of TIL in LSCC. A meta-analysis was performed including all studies assessing the association between TIL counts in hematoxylin-eosin (HE)-stained sections, for CD8+ and/or CD3+/CD4+ TIL and overall survival (OS) or disease-free survival (DFS). The pooled meta-analysis showed a favorable prognostic role for stromal TIL in HE sections for OS (HR 0.57, 95% CI 0.36–0.91, p = 0.02), and for DFS (HR 0.56, 95% CI 0.34–0.94, p = 0.03). High CD8+ TIL were associated with a prolonged OS (HR 0.62, 95% CI 0.4–0.97, p = 0.04) and DFS (HR 0.73, 95% CI 0.34–0.94, p = 0.002). High CD3+/CD4+ TIL demonstrated improved OS (HR 0.32, 95% CI 0.16–0.9, p = 0.03) and DFS (HR 0.23, 95% CI 0.10–0.53, p = 0.0005). This meta-analysis confirmed the favorable prognostic significance of TIL in LSCC. High stromal TIL evaluated in HE sections and intra-tumoral and stromal CD3+, CD4+ and/or CD8+ TIL might predict a better clinical outcome.

7 July 2011 in Head & Neck
Verified
Journal Article
Closed access
PDF file
APAndres Coca Pelaz
Andres Coca Pelaz
Juan Pablo Rodrigo TapiaJuan Pablo Rodrigo Tapia
Juan Pablo Rodrigo Tapia
CSCarlos Suárez
Carlos Suárez